EP2343988A1 - Nmp-containing extract, a method of its production and uses thereof - Google Patents
Nmp-containing extract, a method of its production and uses thereofInfo
- Publication number
- EP2343988A1 EP2343988A1 EP09756673A EP09756673A EP2343988A1 EP 2343988 A1 EP2343988 A1 EP 2343988A1 EP 09756673 A EP09756673 A EP 09756673A EP 09756673 A EP09756673 A EP 09756673A EP 2343988 A1 EP2343988 A1 EP 2343988A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- nmp
- coffee
- extract
- nrf2
- trigonelline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F5/00—Coffee; Coffee substitutes; Preparations thereof
- A23F5/04—Methods of roasting coffee
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F5/00—Coffee; Coffee substitutes; Preparations thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
Definitions
- the present invention relates to a N-methylpyridinium cation (NMP)-containing extract, a method for its production, uses of said NMP-containing extract as a dietary supplement and for the prevention or reduction of oxidative stress, and to foodstuff containing said extract.
- NMP N-methylpyridinium cation
- phase Il enzymes are part of the biotransformation and play a critical role by converting reactive electrophiles or xenobiotics into less toxic products.
- the balance between the phase I potentially carcinogen-activating and the phase Il detoxifying enzymes seems to be critical for the risk to develop cancer. For example, a deficiency in phase Il enzyme activity is associated with an increased risk of colon cancer.
- phase Il detoxifying genes are regulated by the activation of the antioxidant or electrophile response elements (ARE ⁇ /EpRE) which are found in the 5'-flanking region of their promoters.
- ARE a cis-active element, is activated via binding of the transcription factor Nrf2 (nuclear factor-erythroid 2 p45 subunit (NF-E2)-related factor 2), a member of the Cap'n'Collar (CNC) family of the basic-region leucine zipper (bZIP) proteins.
- Nrf2 transcription factor-erythroid 2 p45 subunit
- CNC Cap'n'Collar
- bZIP basic-region leucine zipper
- Nrf2 is sequestered in the cytoplasm in a complex with Keapi , an E3 ubiquitin ligase substrate adaptor. Initiated by ROS or upstream protein kinases, Keapi inactivation leads to a translocation of Nrf2 into the nucleus, binding to the ARE and the onset of the expression of phase Il enzymes.
- Genes which are regulated by Nrf2 include glutathione S- transferases (GST), UDP-glucuronyltransferases (UGT), ⁇ -glutamate cysteine ligases ( ⁇ GCI_), NAD(P)H-quinone oxidoreductase 1 (NQO1) and heme oxygenase 1 (HO1).
- Nrf2 plays a crucial role in the regulation of xenobiotic metabolizing enzymes.
- the technical problem underlying the present invention is to provide a product or other means for the prevention or reduction of oxidative stress which might be used for example as a dietary supplement.
- the present invention relates to a method for producing a N- methylpyridinium (NMP)-containing extract from trigonelline-containing organic material, said extract containing at least 1.9% (w/w) NMP, the method comprising the steps of:
- step (c) treating the aqueous extract obtained in step (b) with polyamide;
- the NMP-containing extract of the present invention is a coffee brewed from extremely dark roasted Brasil coffee beans. This coffee is hereinafter sometimes designated as "coffee 5".
- the NMP-containing extract obtainable by the present invention contains at least 1.9% (w/w) NMP, more preferably at least 2.5% (w/w) NMP. Further, the NMP-containing extract of the present invention can contain at least 0.1 mg/g isomers of N-methylpicolinium.
- NMP N-methylpyridinium
- the NMP-containing extract of the present invention contains at most 0.27% (w/w) trigonelline.
- the NMP-containing extract of the present invention contains at most 0.31% (w/w) chlorogenic acid.
- the NMP-containing extract of the present invention contains less than 0.001 %.(w/w) catechol.
- trigonelline-containing organic material as used herein relates to any naturally occurring material that contains the alkaloid trigonelline.
- the trigonelline-containing organic material is selected from the group consisting of coffee, in particular Coffea arabica, Coffea canephora, Coffea spp., and Psilanthus spp., members of the Fabaceae, in particular Pisum sativum, Glycine max, Phaseolus vulgaris, Lens culinaris, Cicer arietinum, and Trigonella foenum-graecum, members of the Chenopodiaceae, in particular Chenopodium quinoa, and members of the Poaceae, in particular Avena sativa.
- the trigonelline-containing organic material is coffee.
- the coffee is an Arabica Columbia coffee.
- the coffee is a Brasil coffee.
- step (a) of the method of the present invention comprises roasting the trigonelline-containing organic material at a temperature of 260 0 C for 5 minutes.
- the temperature and length of time for step (a) of the method according to the present invention is usually adopted to achieve a NMP-content in the roasted trigonelline-containing organic material of at least 1.1 mg NMP per gram of roasted trigonelline-containing organic material.
- Step (b) of the method of the present invention comprises treating the roasted trigonelline-containing organic material particularly for 1 to 60 minutes with water having a temperature of 10 0 C to 100 0 C, preferably for 5 to 30 minutes with water having a temperature of 50 0 C to 98°C, more preferably for 10 to 20 minutes with water having a temperature of 7O 0 C to 97 0 C.
- step (b) of the method of the present invention comprises treating the roasted trigonelline-containing organic material for 15 minutes with water having a temperature of 90-95 0 C.
- the roasting of the trigonelline-containing organic material as well as the hot water extraction can be carried out by methods well known in the art.
- step (c) of the method of the present invention comprises treating the aqueous extract with polyamide for 1 to 120 minutes, preferably for 10 to 90 minutes, more preferably for 20 to 60 minutes.
- step (c) of the method of the present invention comprises treating the aqueous extract with polyamide for 30 minutes.
- the polyamide-treated aqueous extract is stable at ambient temperature for at least 10 days without the occurrence of precipitates.
- the polyamide treatment as well as the cation exchange chromatography can be carried out by methods well known in the art.
- the polyamide treatment removes polyphenols by adsorption and clarifies the filtrate from particles, wherein any type of polyamide in a powdered form can be used.
- the cation exchange chromatography uses a weak cation exchange resin. In a preferred embodiment, this resin is Purolite® C104E resin.
- the cation exchange chromatography is carried out according to the column method. In yet another preferred embodiment, the cation exchange chromatography is carried out according to the batch method.
- the method of the present invention can further comprise the steps of filtering the aqueous extract prior to and/or after step (c).
- Step (d) of the method according to the present invention can further comprise elution of the NMP-containing extract by 20% aqueous formic acid or 1 M HCI. Elution with 20% aqueous formic acid is especially preferred.
- the method of the present invention can comprise a step of further extracting an aqueous solution of the extract obtained in step (d) with ethyl acetate to decaffeinate the extract. This step can be carried out by methods well known in the art.
- the present invention also relates to the use of said N- methylpyridinium (NMP)-containing extract as a dietary supplement.
- the use of said N-methylpyridinium (NMP)- containing extract as a dietary supplement comprises the daily intake of at least 500 ml of coffee 5 for at least four weeks.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising, in a therapeutically effective amount, said N- methylpyridinium (NMP)-containing extract according to the present invention, optionally in combination with one or more pharmaceutically acceptable excipient(s) and/or carrier(s) and/or diluent(s) and/or solvent(s) and/or salt(s) and/or buffer(s).
- the pharmaceutical composition according to the present invention can have any suitable form that is known in the art. Preferably, it is a solid form, a liquid form or in form of an aerosol.
- Administration of the pharmaceutical composition according to the present invention can be in any suitable form known in the art, e.g. orally, intravenously, intradermal ⁇ , intraperitoneal ⁇ , intramuscularly or by inhalation.
- the pharmaceutical composition according to the present invention are suited for the prevention or reduction of oxidative stress and for the prevention or reduction of disorders and/or diseases related to oxidative stress.
- the present invention relates to a method for the prevention or reduction of oxidative stress and for the prevention of disorders and/or diseases related to oxidative stress, said method comprising administering to a subject a N-methylpyridinium (NMP)-containing extract of the present invention and/or a medicament and/or a pharmaceutical composition of the present invention.
- NMP N-methylpyridinium
- Such administration is not subjected to any particular limitations and can be in any form known in the art, e.g. orally, intravenously, intradermal, intraperitoneal or intramuscular.
- the subject is a human.
- oxidative stress as used herein relates to any imbalance between the production of reactive oxygen species and a biological system ' s ability to readily detoxify these reactive oxygen species or easily repair the resulting damage.
- the disorders and/or diseases related to oxidative stress are selected from the group containing cancers, neurodegenerative diseases, cardiovascular diseases, atherosclerosis, aging and other pathophysiological conditions associated with oxidative stress such as treatment with extracorporal organ substition methods (dialysis, heart-lung machine).
- the disorder and/or disease related to oxidative stress is cancer.
- the cancer is selected from the group consisting of colon cancer, bladder cancer, lung cancer, breast cancer, prostate cancer, endometrial cancer, and gastrointestinal tract cancer.
- the present invention relates to foodstuff that is enriched with N-methylpyridinium (NMP) by the addition of said NMP-containing extract according to the present invention.
- NMP N-methylpyridinium
- foodstuff as used herein relates to any substance that can be eaten or drunk by an animal or a human for example for nutrition and/or pleasure.
- the foodstuff is coffee.
- the present invention also relates to a coffee blend comprising at least two different coffees that are roasted by different methods and/or to different degrees.
- the coffee blend of the present invention comprises two different coffees that are of the same provenance.
- the coffee blend of the present invention comprises two different coffees that are of different provenance.
- the coffees can be selected from the group containing Arabica Brasil coffee, Arabica Columbia coffee, and Robusta coffee.
- the different roasting methods comprise fluidized bed roasting and drum roasting.
- the different roasting degrees comprise a light to middle dark degree of roasting, and a dark to very dark degree of roasting.
- the coffee blend according to the present invention is composed of 25% (wt/wt) coffee that has been roasted by fluidized bed roasting to a light to middle dark degree, and 75% (wt/wt) coffee that has been roasted by drum roasting to a dark degree.
- the method for producing such a coffee blend comprises roasting green coffee beans in a first set of roasting in a fluidized bed roaster (representing a predominant energy transfer to the coffee beans by convection) within 1.5 to 3 minutes to a roast colour of 70 to 90 scalepoints, and roasting green coffee beans in a second set of roasting in a drum roaster (representing an energy transfer to the coffee beans by conduction and convection) within 10 to 30 minutes reaching a roast colour of 40 to 60 scalepoints.
- the coffee blend of the present invention is made by roasting green coffee beans in a first set of roasting in a fluidized bed roaster (representing a predominant energy transfer to the coffee beans by convection) within 1.5 to 3 minutes to a roast colour of 70 to 90 scalepoints.
- a second set of roasting green coffee beans were roasted in a drum roaster (representing an energy transfer to the coffee beans by conduction and convection) within 10 to 30 minutes reaching a roast colour of 40 to 60 scalepoints.
- the coffee blend consists of Brasil coffees.
- the coffee blend is characterized by a low trigonelline content, a high chlorogenic acid content, and a very high N-methylpyridinium (NMP) content and niacin content.
- the coffee blend contains at least 73 ⁇ g/ml NMP.
- Figure 1 Inhibition of cell growth by 1-methyl-4-phenyIpyridinium iodide (MPPI) and NMPI. Growth inhibition was determined using a sulforhodamine B (SRB) assay. HT29 cells were incubated for 24h with the respective compounds. Growth inhibition was calculated as survival of treated cells over control cells (treated with the vehicle 1% DMSO) x 100 (T/C %). The values given are the means ⁇ SD of at least three independent experiments.
- MPPI 1-methyl-4-phenyIpyridinium iodide
- SRB sulforhodamine B
- FIG. 4 Western blot analysis of Nrf2 nuclear concentration in HT29 cells after 3h treatment with MPPI and NMPI. ⁇ -tubulin was included in the test as loading control. The data presented are the means ⁇ SD of at least three independent experiments with similar outcome. Effects were calculated as survival of treated cells over control cells (treated with the vehicle 1% DMSO) x 100 (T/C %).
- FIG. 5 Real time PCR of GST1A1 , -A2, -P, -T gene transcription in HT29 cells after 3h (A) and 24h (B) treatment with NMPI.
- the data presented are the mean ⁇ SD of four independent experiments in a double measurement with similar outcome.
- Relative transcription of the solvent control (1% DMSO) equals 1.
- FIG. 6 Real time LJGT1A1 gene transcription in HT29 cells after 3h (A) and 24h (B) treatment with NMPI.
- the data presented are the mean ⁇ SD of four independent experiments in a double measurement with similar outcome.
- Relative transcription of the solvent control (1% DMSO) equals 1.
- Figure 7 Real time ⁇ GCI_ gene transcription in HT29 cells after 3h (A) and 24h (B) treatment with NMPI.
- the data presented are the mean ⁇ SD of four independent experiments in a double measurement with similar outcome.
- Relative transcription of the solvent control (1% DMSO) equals 1.
- Figure 8 Real time HO1 gene transcription in HT29 cells after 3h (A) and 24h (B) treatment with NMPI.
- the data presented are the mean ⁇ SD of four independent experiments in a double measurement with similar outcome.
- Relative transcription of the solvent control (1% DMSO) equals 1.
- Figure 9 Real time NQO1 gene transcription in HT29 cells after 3h (A) and 24h (B) treatment with NMPI.
- the data presented are the mean ⁇ SD of four independent experiments in a double measurement with similar outcome.
- Relative transcription of the solvent control (1% DMSO) equals 1.
- FIG 10 Real time Nrf2 gene transcription in HT29 cells after 3h (A) and 24h (B) treatment with NMPI.
- the data presented are the mean ⁇ SD of four independent experiments in a double measurement with similar outcome.
- Relative transcription of the solvent control (1% DMSO) equals 1.
- FIG 11 Real time PCR gene transcription of GST1A1 , -A2, -P, -T, ⁇ GCl_, HO1 , NQO1 and UGT1A1 in PBLs after 3h treatment with NMPI and 3h treatment with NMP-rich coffee (coffee 5).
- the data presented are a double measurement of a single experiment with similar outcome.
- Relative transcription of the solvent control (1% DMSO) equals 1.
- Figure 12 Real time PCR of GST1A1 , -A2, -P, -T (A) and ⁇ GCI_, HO1 , NQO1 (B) gene transcription in human PBLs after four weeks daily consumption of 500 mL NMP-rich coffee (coffee 5).
- the data presented are the median, mean ⁇ SD of 18 independent experiments in a double measurement with similar outcome.
- Relative transcription wash-out two weeks abstinence of coffee
- Figure 13 Real time PCR of Nrf2 gene transcription in human PBLs after four weeks daily consumption of 500 mL NMP-rich coffee (coffee 5). The data presented are the median, mean ⁇ SD of 18 independent experiments in a double measurement with similar outcome. Relative transcription wash-out (two weeks abstinence of coffee) equals 1.
- Figure 14 Profile of NMP elution applying 20% aqueous formic acid as eluent in fractionated elution.
- Figure 15 Calibration of d 3 -NMP using unlabeled NMP to overcome adulterations originating from incompletely labeled internal standard. Each standard mixture was analyzed in quadruplicate. Equation is obtained by linear regression analysis.
- Y-axis ratio (area NMP/ area d 3 -NMP), x-axis ratio (concentration NMP/ concentration d 3 -NMP).
- NMPI does not mediate growth inhibitory effects up to 500 ⁇ M, with 92.1 ⁇ 12.8 % cell growth in the highest concentration.
- MPPI strongly inhibits cell growth already at a concentration of 1 ⁇ M, decreasing cell growth to 32.7 ⁇ 1.3 % at 500 ⁇ M.
- the data demonstrate that MPPI and NMPI substantially differ with respect to their cytotoxic properties. Whereas MPPI is strongly cytotoxic, NMPI is well tolerated by the cells up to 500 ⁇ M.
- Nrf2 translocation into the nucleus was determined in HT29 cells.
- the nuclear translocation of Nrf2 is the crucial step to successful Nrf2-mediated antioxidative signaling. Only increased concentrations of Nrf2 in the nucleus lead downstream to the onset of antioxidant phase Il enzyme expression. Nrf2 translocation was investigated after 3 h incubation by Western blot analysis.
- NMPI leads already in nanomolar concentrations (0.1 ⁇ M) to an increased Nrf2 concentration in the nuclear fraction without decrease of the cytosolic Nrf2 protein content ( Figure 2).
- An influence of NMPI on the de novo synthesis of Nrf2 has to be considered since there is no loss of Nrf2 in the cytosolic fraction.
- Nrf2 translocation into the nucleus was observed in a concentration-dependent manner from 100 ⁇ M up to 500 ⁇ M, accompanied by a decrease of Nrf2 in the cytosolic fraction.
- MPPI as a known toxic substance which induces oxidative cell stress also influences Nrf2 translocation
- Western blot analysis after 3 h incubation with MPPI was performed.
- MPPI in comparison to NMPI shows no effect on the nuclear translocation of Nrf2 between 0.01 and 10 ⁇ M MPPI.
- MPPI strongly decreases cytosolic and nuclear Nrf2 protein which may be due to the observed cytotoxic effects.
- Nrf2 nuclear translocation by NMPI (Figure 2) in human colon carcinoma cells causes the onset of the transcription of selected ARE-dependent genes, such as GST-isoenzymes GST1A1 , -A2, -P and -T, was investigated by real time PCR gene expression analysis. Only an increased gene transcription of these antioxidative enzymes can protect the cells effectively from oxidative attacks. To investigate whether the modulation of the transcription can be seen as a result of enhanced Nrf2 nuclear translocation, the incubation time and the NMPI concentrations were aligned to the translocation studies. Furthermore a 24h incubation was added to examine long term effects on gene transcription.
- ARE-dependent genes such as GST-isoenzymes GST1A1 , -A2, -P and -T
- ⁇ GCI_, HO1 , NQO1 and UGT1A1 were also tested on transcriptional changes after 3h and 24h incubation with NMPI.
- 3h incubation of NMPI leads from 10 to 100 ⁇ M to an increase of UGT1A1 transcripts which indicates that the nuclear translocation of Nrf2 downstream leads to enhanced antioxidative signaling.
- this effect seems also to prolong up to 24h ( Figure 6B).
- ⁇ GCI_ as a further Nrf2-regulated antioxidative phase Il enzyme, was tested on transcriptional changes after 3h incubation with NMPI.
- NQO1 is also discussed as very sensitively regulated by the transcription factor Nrf2 and was therefore tested by real time PCR. As shown in Figure 9, A and B, only 24h incubation with NMPI seems to affect gene transcription of NQO1. 10 ⁇ M NMPI strengthens NQO1 transcription about 3-fold.
- NMPI does not only lead to a strong induction of Nrf2 nuclear translocation. This antioxidative signaling is transferred downstream and leads to a strong induction of different AFtE- mediated genes.
- these effects seem to be not only a short time induction (3h) of antioxidative and detoxifying protection since the observed transcriptional changes appear even stronger after 24h incubation with NMPI.
- Nrf2 concentration in the cytoplasm is closely regulated by the balance between Nrf2 protein de novo synthesis and proteasomal Nrf2 protein degradation. This leads, by allowing the rapid turnover of Nrf2, to a constant Nrf2 concentration in the cytoplasm under unstressed conditions. It is known that oxidative/electrophile stress provokes the nuclear accumulation of de novo- synthesized Nrf2 protein. To address the question whether nuclear translocation of Nrf2 by NMPI is fortified by an increased de novo synthesis of Nrf2, the level of Nrf2 transcripts were determined by quantitative real time PCR.
- Example 5 Influence of NMPI on human peripheral blood lymphocytes ex vivo
- PBL peripheral blood lymphocytes
- Nrf2 transcription was examined in freshly isolated human PBLs, 3h incubated with NMPI and coffee 5. As shown in Figure 11 , the isolated compound NMPI as well as the NMP-rich coffee 5 strongly increased Nrf2 transcript levels by 1.5- respectively 2.1 -fold.
- Example 6 Influence of NMP-rich coffee in vivo
- Nrf2 transcription was also determined.
- the four week consumption of the NMP-rich coffee 5 lead in the majority of test persons to a potent increase of Nrf2- transcripts.
- Nrf2 transcription was in the mean raised up to 3.2-fold. This result indicates that the above seen induced transcription of important ARE-mediated genes is also supported by a potent induction of Nrf2 transcription in human PBLs after four weeks consumption of coffee 5.
- Nrf2/ARE pathway may therefore be the underlying mechanism by which NMPI and NMP-rich coffee leads to an activation of protection against oxidative stress.
- Example 7 Experimental protocol for food-grade isolation of a NMP-rich extract from roast coffee
- the suspension was filtered through Whatman filter paper under vacuum yielding a clear solution free of particles or colloids.
- the filter cake was washed with water (25 ml, 0.5 eq) and the filtrates were combined.
- the solution was applied on a column (3 cm x 50 cm, with water cooling, P3 frit) of cation exchange resin Purolite® C104E (weak cation exchange resin, hydrogen form, 250 ml, 1 bedvolume (BV)) pre-treated following the manufacturer ' s protocol.
- the resin was washed with demineralized water (4 BV, Millipore quality) followed by elution with aqueous formic acid (20 %, 4 BV) or 1 M hydrochloric acid (2 BV).
- the extract obtained by this procedure contained >74 % of the NMP cation present in the coffee powder used for isolation.
- Example 8 Isolation of an NMP-rich extract from roasted coffee
- the initial content of NMP in the roast coffee powder used for isolation purposes was determined by HPLC-MS/MS analysis using stable isotope dilution analysis (cf. Example 9).
- Coffee powder was extracted with hot water in a coffee making machine and the brew was analysed for determination of a reference figure. The concentration was 73.7 mg/l ⁇ 4.9%. Backcalculating to the amount of coffee powder (48 g/900 ml, resulting in 800 ml beverage) this was a concentration of 1.23 mg/g.
- Table 1 Extraction yields of N-methylpyridinium
- the coffee extract obtained was treated with polyamide powder and filtered resulting in a clear solution free of particles and colloids. Treated this way, the brew was stable for 10 days at ambient temperature, and no precipitate occurred.
- the capacity of the cation exchanger used was sufficient to cover the cation content of a solution obtained from 100 g extracted coffee powder. Neither in the eluate, nor in the rinsing fraction any NMP could be detected by HPLC- MS/MS.
- NMP recovered by elution of the cation exchanger column was 84 % based on HPLC-MS/MS analysis of the eluates, equalling 74.0 % of the NMP content in the coffee powder used for isolation.
- Sample preparation involved separation of the analyte and the internal standard from matrix compounds by solid phase extraction on cation exchange material and resulted in clear, uncolored solutions which were ready for HPLC-MS/MS analysis after dilution.
- the HPLC-method was shortened to 10 minutes of analysis to allow a higher throughput of samples.
- HPLC-MS/MS The Agilent 1200 Series HPLC-system consisted of a pump, a degasser and an autosampler (Agilent, Waldbronn, Germany) and was connected to a 3200 API triple quadrupole (Applied Biosystems/MDS Sciex, Darmstadt, Germany) with an electrospray ionization (ESI) device running in positive ionization mode.
- Nebulizer gas and curtain gas were nitrogen and set at 65 psi and 25 psi, respectively.
- Heater gas was set at 60 psi, the temperature was 350 °C.
- Detection was performed in multiple reaction monitoring (MRM) mode, recording the transitions from the parent ion [M] + to the fragments after collision-induced dissociation.
- MRM multiple reaction monitoring
- aqueous solutions of NMP and trideuterated NMP were individually infused using a syringe pump at a flow of 10 ⁇ l/min and the parameters for the mass transitions were optimized using the ..quantitative optimization"-tool provided by the software (Analyst 1.4.1 , Sciex, Toronto, Canada).
- Analyte m/z 94 -> m/z 79, m/zlQ, m/z 52, internal standard m/z 97 -> m/z 79, m/z 78, m/z 52.
- the declustering potential (DP) was 50
- the cell exit potential (CXP) was 15, and the collision energy (CE) was 33.
- the dwell time for each mass transition was 100 ms.
- the quadrupoles operated at unit mass resolution, ion spray voltage was 5500 V.
- Chromatography was on a GROM-SH80 SCX column (50 mm x 2 mm, 5 ⁇ m, Grom,dorfberg, Germany) at a flow of 400 ⁇ l/min with isocratic elution (10 min).
- Aqueous methanol (50%) containing ammoniumacetate as modifier (50 mM) was used.
- Sample preparation for analysis of NMP in extracts and coffee brew. An aliquot of the fractions collected, respectively the unfractionated coffee brew and the polyamide-treated coffee brew, was spiked with the internal standard d 3 -N- methylpyridinium (1.5 ⁇ mol/ml, 100 ⁇ l/ml sample). After dilution (1 +9, v/v with water), an aliquot (1 ml) was applied on a SPE-cartridge (CBA, 1 g, 6 ml, Varian, Darmstadt) preconditioned with methanol and water (5 ml each).
- CBA SPE-cartridge
- Trigonelline was determined by means of stable isotope dilution analysis with d 3 -trigonelline, synthesized from nicotinic acid and d3-methyliodide as internal standard. An aliquot (50 ⁇ l) of an aqueous solution of the extract (3 mg/ml) was spiked with d 3 -trigonelline (1 mM, 25 ⁇ l) and diluted with water to a final volume of 50 ml. 5 ⁇ l were analyzed by HPLC-MS/MS.
- NMP was determined by means of stable isotope dilution analysis with d 3 -NMP synthesized from pyridine and ds-methyliodide as internal standard. Quantitative analysis was performed as described in Example 9.
- Catechol was determined by means of stable isotope dilution analysis with d 4 - catechol, synthesized from catechol and deuteriumoxide, as internal standard. An aliquot (1 ml) of an aqueous solution of the extract (3 mg/ml) was spiked with d 4 -catechol (3 mM, 1 ⁇ l). After equilibration and membrane filtration (0.45 ⁇ m), an aliquot (5 ⁇ l) was analyzed by HPLC-MS/MS.
- Chlorogenic acid and caffeine An aqueous solution of the extract (3 mg/ml) was diluted with water (1/10) and 10 ⁇ l were injected into a HPLC-DAD system (324 nm for CQA, 272 nm for caffeine). Quantitation was performed by external calibration using 5-chlorogenic acid and caffeine standard solutions.
- Sodium, calcium, potassium, magnesium An aqueous solution of the extract (3 mg/ml) was used for analysis. The compounds were quantitated by inductive coupled plasma (ICP) with external calibration. The wavelengths applied were 317.933 (calcium), 766.490 (potassium), 285.213 (magnesium), and 589.592 (sodium).
- ICP inductive coupled plasma
- the lyophilized material obtained by elution after cation exchange chromatography was analyzed for anorganic cations, chlorogenic acids, caffeine, trigonelline, N-methylpyridinium and catechol (cf. Table 5).
- Dataset A Data was obtained from extracts obtained after extraction and treatment of coffee following the procedure of Example 7.
- Dataset B Data was obtained from extracts obtained after extraction and treatment of coffee following the procedure of Example 7 and additional extraction with ethylacetate.
- NMP and related compounds have been identified as potent activators of Nrf2-mediated gene expression.
- the Nrf2/ARE pathway represents a fundamental mechanism by which cellular defense can be triggered.
- NMP and related substances effectively increase the expression of elementary detoxifying phase Il enzymes by translocation of Nrf2 into the nucleus as well as the induction of Nrf2 de novo synthesis. These effects are not limited to in vitro test systems but are even more pronounced in humans.
- NMP in its ionic form as NMP iodide (NMPI), represents a natural constituent in roasted trigonelline-containing material and its concentration can be triggered by modulation of the roasting conditions.
- N-methylpicolinium products such as N- methyl 2-, -3-, and 4-piccolinium (NM2P, NM3P and NM4P) are generated.
- the content of these substances in the roasted coffee bean depends on the degree and the time of roasting.
- Testing of a modulation of Nrf2 nuclear translocation of NM2-,3- and 4Pl showed effects on this pathway.
- An increase in total Nrf2 protein content, as well as a potent Nrf2 nuclear translocation was detected from 100 ⁇ M.
- the substances seem also to exhibit a positive influence on cells with respect to a protection against attacks from oxidative noxes and the augmentation of their concentration may be a promising way to generate a bioactive coffee beverage.
- Nrf2 represents a promising target, by which the onset of cellular defense mechanisms against oxidative stress can be enhanced. Especially, the aim to identify bioactive food constituents protecting cells against attacks from electrophiles and ROS through the onset of the Nrf2/ARE pathway seems to be promising. So far, the majority of compounds which have been reported to induce Nrf2 translocation into the nucleus belong to the class of polyphenols. So far, NMP has not been reported as activators of Nrf2/ARE-regulated gene expression. Hence, it seems to be very appealing to use NMP-rich extracts for the production of functional food products enhancing the natural defence mechanisms, as well as for the manufacture of medicaments for the prevention or reduction of oxidative stress and for the prevention of disorders and/or diseases related to oxidative stress.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Tea And Coffee (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09756673A EP2343988A1 (en) | 2008-11-13 | 2009-11-12 | Nmp-containing extract, a method of its production and uses thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08019851A EP2186419A1 (en) | 2008-11-13 | 2008-11-13 | NMP-containing extract, a method of its production and uses thereof |
| PCT/EP2009/008070 WO2010054818A1 (en) | 2008-11-13 | 2009-11-12 | Nmp-containing extract, a method of its production and uses thereof |
| EP09756673A EP2343988A1 (en) | 2008-11-13 | 2009-11-12 | Nmp-containing extract, a method of its production and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP2343988A1 true EP2343988A1 (en) | 2011-07-20 |
Family
ID=40512291
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP08019851A Withdrawn EP2186419A1 (en) | 2008-11-13 | 2008-11-13 | NMP-containing extract, a method of its production and uses thereof |
| EP09756673A Ceased EP2343988A1 (en) | 2008-11-13 | 2009-11-12 | Nmp-containing extract, a method of its production and uses thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP08019851A Withdrawn EP2186419A1 (en) | 2008-11-13 | 2008-11-13 | NMP-containing extract, a method of its production and uses thereof |
Country Status (3)
| Country | Link |
|---|---|
| EP (2) | EP2186419A1 (en) |
| RU (1) | RU2011117027A (en) |
| WO (1) | WO2010054818A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2382868A1 (en) * | 2010-04-30 | 2011-11-02 | Tchibo GmbH | Healthy coffee and method of its production |
| EP2601844B1 (en) | 2011-12-05 | 2015-10-21 | Plantextrakt GmbH&Co. Kg | Method of producing an extract enriched with trigonelline (TRIG) and/or chlorogenic acids (CQA) |
| CN105255780A (en) * | 2015-11-12 | 2016-01-20 | 中国农业大学 | Combination increasing yield of alfalfa and improving quality of alfalfa and application thereof |
| JP7819541B2 (en) * | 2022-03-11 | 2026-02-25 | 株式会社島津製作所 | Analysis method for coffee components |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH523023A (en) * | 1969-11-14 | 1972-05-31 | Hag Ag Bremen | Prevention of chemisorption of chlorogenic acid of - coffee extracts |
| US3780197A (en) * | 1970-07-27 | 1973-12-18 | Gen Foods Corp | Balanced coffee flavors |
| US3640726A (en) * | 1970-11-25 | 1972-02-08 | Procter & Gamble | Flavor robusta coffee |
| US3725076A (en) * | 1970-12-21 | 1973-04-03 | Gen Foods Corp | Coffee of improved aroma and freshness retention |
| US4005227A (en) * | 1972-04-13 | 1977-01-25 | Firmenich & Cie | Flavoring agent |
| US4053652A (en) * | 1975-08-25 | 1977-10-11 | General Foods Corporation | Roasted and ground coffee product and method |
| JPS6261569A (en) * | 1985-09-12 | 1987-03-18 | Morinaga & Co Ltd | Process for producing colorless or light-colored beverages |
| DE3915535A1 (en) * | 1989-05-12 | 1990-11-15 | Mai Jutta | Compsns. for treating skin disorders - contain trigonellin or trigonellic acid |
| CA2105018C (en) * | 1992-09-10 | 1998-06-23 | Mary R. Jensen | High-yield roasted coffee with balanced flavor |
| US5721005A (en) * | 1995-08-16 | 1998-02-24 | The Procter & Gamble Company | Fast roasted coffee providing increased brew strength and darker cup color with desirable brew acidity |
| FR2793245B1 (en) * | 1999-05-05 | 2002-10-11 | Adir | NOVEL SUBSTITUTED PYRIDINIC OR PIPERIDINIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| IES990741A2 (en) * | 1999-09-02 | 2001-04-04 | David Mckernan | A manufacturing process for coffee products |
| JP2003526349A (en) * | 2000-03-13 | 2003-09-09 | ザ プロクター アンド ギャンブル カンパニー | Novel roasted coffee with balanced flavor and method for producing the same |
| PL364348A1 (en) * | 2004-01-12 | 2005-07-25 | PHARMENA Sp.z o.o. | Application of quaternary pyridine salts as vessel protection agent |
| PL381862A1 (en) * | 2007-02-28 | 2008-09-01 | Trigendo Spółka Z Ograniczoną Odpowiedzialnością | Application of pyridine compounds and the manner of treatment |
| JP2009023932A (en) * | 2007-07-18 | 2009-02-05 | Tama Tlo Kk | Antiviral agent containing n-methylpyridinium compound as active ingredient, and antiviral composition, diet and fodder for animal, containing the same |
-
2008
- 2008-11-13 EP EP08019851A patent/EP2186419A1/en not_active Withdrawn
-
2009
- 2009-11-12 EP EP09756673A patent/EP2343988A1/en not_active Ceased
- 2009-11-12 RU RU2011117027/10A patent/RU2011117027A/en not_active Application Discontinuation
- 2009-11-12 WO PCT/EP2009/008070 patent/WO2010054818A1/en not_active Ceased
Non-Patent Citations (1)
| Title |
|---|
| See references of WO2010054818A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010054818A1 (en) | 2010-05-20 |
| EP2186419A1 (en) | 2010-05-19 |
| RU2011117027A (en) | 2012-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jeszka-Skowron et al. | Comparison of methylxantines, trigonelline, nicotinic acid and nicotinamide contents in brews of green and processed Arabica and Robusta coffee beans–Influence of steaming, decaffeination and roasting processes on coffee beans | |
| Macrae | Nitrogenous components | |
| Xu et al. | Quality development and main chemical components of Tieguanyin oolong teas processed from different parts of fresh shoots | |
| Dziki et al. | Ground green coffee beans as a functional food supplement–Preliminary study | |
| Asenstorfer et al. | Chemical structure of flavonoid compounds in wheat (Triticum aestivum L.) flour that contribute to the yellow colour of Asian alkaline noodles | |
| Tong et al. | Inhibiting enzymatic starch digestion by hydrolyzable tannins isolated from Eugenia jambolana | |
| Yang et al. | Analysis of coumarin and its glycosidically bound precursor in Japanese green tea having sweet-herbaceous odour | |
| EP1893034B1 (en) | Processes for isolating bitter compounds for use in food and beverage products | |
| EP2000034A2 (en) | Method for production of chlorogenic acid-containing material | |
| SG184990A1 (en) | Healthy coffee and methods of its production | |
| Lee et al. | Effect of organic acid-soaking and sonication on the formation of volatile compounds and α-dicarbonyl compounds in Robusta coffee | |
| EP2433625A1 (en) | Anti-obesity agent comprising compound containing benzotropolone ring | |
| EP2186419A1 (en) | NMP-containing extract, a method of its production and uses thereof | |
| Joubert et al. | Occurrence and sensory perception of Z-2-(β-D-glucopyranosyloxy)-3-phenylpropenoic acid in rooibos (Aspalathus linearis) | |
| Mubarak et al. | Comparison of liberica and arabica coffee: Chlorogenic acid, caffeine, total phenolic and DPPH radical scavenging activity | |
| EP2517577B1 (en) | A method for producing soy sauce having hypotensive effects | |
| WO2011074538A1 (en) | Tea polyphenols and method for producing same | |
| Portillo et al. | Caffeine | |
| Landi et al. | Valle Agricola lentil, an unknown lentil (Lens culinaris Medik.) seed from Southern Italy as a novel antioxidant and prebiotic source | |
| WO2010051216A1 (en) | Recovery of antioxidants from decaffeination process | |
| Zhong et al. | Cation-exchange/hydrophilic interaction mixed-mode liquid chromatographic method for analyzing the trigonelline class of bioactives in coffee beans | |
| Gulshan et al. | Influence of brewing method on the nutritional composition and sensory attributes of coffee by Arabica beans of different roasting degrees | |
| AU2014100873A4 (en) | Quantitative Analysis of the Flavonoid Glycosides and Terpene Trilactones in the Extract of Ginkgo biloba and Evaluation of their Inhibitory Activity towards ß-Amyloid Peptide Aggregation | |
| Herawati et al. | Antioxidant, anti-α-glucosidase and anti-glycation activities of coffee brew from Robusta coffee beans roasted at different levels. | |
| JP5872725B1 (en) | Dipeptidyl peptidase IV inhibitory composition derived from bonito |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20110414 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: AL BA RS |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: MARKO, DORIS Inventor name: HOFMANN, THOMAS Inventor name: SOMOZA, VERONIKA Inventor name: EISENBRAND, GERHARD Inventor name: EGGERS, RUDOLF Inventor name: LANTZ, INGO Inventor name: STIEBITZ, HERBERT Inventor name: BYTOF, GERHARD |
|
| DAX | Request for extension of the european patent (deleted) | ||
| 17Q | First examination report despatched |
Effective date: 20120419 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
| 18R | Application refused |
Effective date: 20130523 |